Business Context and Reporting Period
Company: Theravance Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Reporting Period: Event-based report regarding investor relations activities scheduled for January 12-15, 2026.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification of a corporate presentation rather than a financial results report.
Material Changes
No material financial changes or operational updates are detailed in the text of this filing. The report focuses solely on the scheduling of investor meetings.
Guidance, Outlook, and Management Commentary
- Investor Meetings: Management will conduct one-on-one meetings with analysts and investors in San Francisco, CA, from January 12-15, 2026.
- Disclosure Method: A slide presentation titled "Corporate Presentation – January 2026" is furnished as Exhibit 99.1 pursuant to Regulation FD.
- Legal Status: The information in this report and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation – January 2026) for actual financial data, pipeline updates, and strategic guidance.
- Verify the specific dates and availability of management for the one-on-one meetings in San Francisco.
- Confirm that the slide deck has been properly filed and is accessible via the SEC EDGAR database.